The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
Abstract
BACKGROUND: In this phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis. METHODS: We randomly assigned patients with a score of 12 or higher on the psoriasis area-and-severity index (PASI, on which scores range from 0 to 72, with higher scores indicating more severe disease) and with 10% or more of their body-surface area affected by psoriasis to receive brodalumab (70 mg, 140 mg, or 210 mg at day 1 and weeks 1, 2, 4, 6, 8, and 10 or 280 mg monthly) or placebo. The primary end point was the percentage improvement from baseline in the PASI score at week 12. Secondary end points included improvement of at least 75% and at least 90% in the PASI score and the score on the static physician's global assessment at week 12. RESULTS: A total of 198 patients underwent randomization. At week 12, the mean percentage improvements in the PASI score were 45.0% among patients receiving 70 mg of brodalumab, 85.9% among those receiving 140 mg, 86.3% among those receiving 210 mg, 76.0% among those receiving 280 mg, and 16.0% among those receiving placebo (P<0.001 for all comparisons with placebo). An improvement of at least 75% and at least 90% in the PASI score at week 12 was seen in 77% and 72%, respectively, of the patients in the 140-mg brodalumab group and in 82% and 75%, respectively, of the patients in the 210-mg group, as compared with 0% in the placebo group (P<0.001 for all comparisons). The percentage of patients with a static physician's global assessment of clear or minimal disease was 26%, 85%, 80%, and 69% with the 70-mg, 140-mg, 210-mg, and 280-mg doses, respectively, of brodalumab, as compared with 3% with placebo (P<0.01 for all comparisons with placebo). Two cases of grade 3 neutropenia were reported in the 210-mg brodalumab group. The most commonly reported adverse events in the combined brodalumab groups were nasopharyngitis (8%), upper respiratory tract infection (8%), and injection-site erythema (6%). CONCLUSIONS: Brodalumab significantly improved plaque psoriasis in this 12-week, phase 2 study. (Funded by Amgen; ClinicalTrials.gov number, NCT00975637.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Nestle, F. O., Kaplan, D. H., & Barker, J. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0804595 · Cited by 2,786
Severe Psoriasis – Oral Therapy with a New Retinoid
Fredriksson, T., & Pettersson, U. (2009) · Dermatologica · doi:10.1159/000250839 · Cited by 2,718
Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
van der Fits, L., Mourits, S., Voerman, J. S. A., Kant, M., Boon, L., Laman, J. D., Cornelissen, F., Mus, A.-M., Florencia, E., Prens, E. P., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802999 · Cited by 2,176
Structure and signalling in the IL-17 receptor family
Gaffen, S. L. (2009) · Nature reviews. Immunology · doi:10.1038/nri2586 · Cited by 1,475
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423
Interleukin-17 and Type 17 Helper T Cells
Miossec, P., Korn, T., & Kuchroo, V. K. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0707449 · Cited by 1,409
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Self-citationAnti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D., & Banerjee, S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109997 · Cited by 936
Self-citationHueber, W., Patel, D. D., Dryja, T., Wright, A. M., Koroleva, I., Bruin, G., Antoni, C., Draelos, Z., Gold, M. H., the Psoriasis Study Group, et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001107 · Cited by 860
Stern, R. S., Nijsten, T., Feldman, S. R., Margolis, D. J., & Rolstad, T. (2004) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.1087-0024.2003.09102.x · Cited by 732
Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses
Zaba, L. C., Cardinale, I., Gilleaudeau, P., Sullivan-Whalen, M., Suárez-Fariñas, M., Fuentes-Duculan, J., Novitskaya, I., Khatcherian, A., Bluth, M. J., Lowes, M. A., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20071094 · Cited by 676
Self-citationCirculating Th17, Th22, and Th1 Cells Are Increased in Psoriasis
Kagami, S., Rizzo, H. L., Lee, J. J., Koguchi, Y., & Blauvelt, A. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.399 · Cited by 640
Psoriasis assessment tools in clinical trials
Feldman, S. R., & Krueger, G. G. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.031237 · Cited by 557
Chronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes
Pène, J., Chevalier, S., Preisser, L., Vénéreau, E., Guilleux, M.-H., Ghannam, S., Molès, J.-P., Danger, Y., Ravon, E., Lesaux, S., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7423 · Cited by 527
Kurd, S. K., & Gelfand, J. M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.09.022 · Cited by 519
Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis
Chandran, V., & Raychaudhuri, S. P. (2010) · Journal of Autoimmunity · doi:10.1016/j.jaut.2009.12.001 · Cited by 510
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Testing the Statistical Certainty of a Response to Increasing Doses of a Drug
Tukey, J. W., Ciminera, J. L., & Heyse, J. F. (1985) · Biometrics · doi:10.2307/2530666 · Cited by 486
Kryczek, I., Bruce, A. T., Gudjonsson, J. E., Johnston, A., Aphale, A., Vatan, L., Szeliga, W., Wang, Y., Liu, Y., Welling, T. H., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4733 · Cited by 470
Genovese, M. C., Van den Bosch, F., Roberson, S. A., Bojin, S., Biagini, I. M., Ryan, P., & Sloan‐Lancaster, J. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27334 · Cited by 451
Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin
Johansen, C., Usher, P. A., Kjellerup, R. B., Lundsgaard, D., Iversen, L., & Kragballe, K. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2008.08902.x · Cited by 352
Rickel, E. A., Siegel, L. A., Yoon, B.-R. P., Rottman, J. B., Kugler, D. G., Swart, D. A., Anders, P. M., Tocker, J. E., Comeau, M. R., & Budelsky, A. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.4299 · Cited by 321
The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex
Wright, J. F., Bennett, F., Li, B., Brooks, J., Luxenberg, D. P., Whitters, M. J., Tomkinson, K. N., Fitz, L. J., Wolfman, N. M., Collins, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2799 · Cited by 316
Homeostatic Regulation of Blood Neutrophil Counts
von Vietinghoff, S., & Ley, K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5183 · Cited by 292
Zhang, L., Yang, X.-Q., Cheng, J., Hui, R.-S., & Gao, T.-W. (2010) · Clinical Immunology · doi:10.1016/j.clim.2009.11.008 · Cited by 211
Immunopathogenesis and role of T cells in psoriasis
Ghoreschi, K., Weigert, C., & Röcken, M. (2007) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2007.08.012 · Cited by 179
Smith, E. E., Stark, M. A., Zarbock, A., Burcin, T. L., Bruce, A. C., Vaswani, D., Foley, P. L., & Ley, K. F. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.2.1357 · Cited by 106
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120225 · Cited by 1,650
Self-citationThe IL-23-IL-17 immune axis: from mechanisms to therapeutic testing
Gaffen, S. L., Jain, R., Garg, A. V., & Cua, D. J. (2014) · Nature reviews. Immunology · doi:10.1038/nri3707 · Cited by 1,585
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citation
Metadata
- Authors
- Papp, K. A., Leonardi, C., Menter, A., Ortonne, J.-P., Krueger, J. G., Kricorian, G., Aras, G., Li, J., Russell, C. B., Thompson, E. H. Z., & Baumgartner, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03-29
- Volume
- 366
- Issue
- 13
- Pages
- 1181-1189
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2127834887
- Cited by
- 941
- References
- 28
- FWCI
- 58.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.